CrackitToday App

Pfizer’s RSV Vaccine

Pfizer’s RSV Vaccine:

The Food and Drug Administration (FDA) has granted approval to Pfizer’s vaccine, Abrysvo, aimed at safeguarding new-borns from respiratory syncytial virus (RSV) by vaccinating pregnant individuals during the latter stages of pregnancy.

  • Abrysvo has been authorized for use in adults aged 60 and above to protect them from RSV.
  • The vaccine generates passive immunity by producing antibodies against RSV in pregnant individuals, which are then passed on to their foetuses in the uterus.
  • Abrysvo’s approval is based on its demonstrated effectiveness in reducing the risk of severe lower respiratory tract disease caused by RSV in new-borns.
  • However, concerns have been raised about potential preterm births in response to the vaccine, similar to issues seen with another competitor vaccine.

Respiratory syncytial virus (RSV) infection:

  • Respiratory syncytial virus (RSV) infection is a common respiratory illness that primarily affects infants, young children, and older adults.
  • RSV belongs to the family of viruses called Paramyxoviridae and is a leading cause of lower respiratory tract infections, such as bronchiolitis and pneumonia, especially in children under the age of two.
  • The virus spreads through respiratory droplets when an infected person coughs or sneezes, and it can also be transmitted through direct contact with contaminated surfaces.